ClinicalTrials.gg
CompletedNCT02114060Updated Oct 16, 2017

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

A Phase 2 interventional study of GEN-003 Vaccine (30μg of each antigen) and GEN-003 Vaccine (60μg of each antigen) in Genital Herpes Simplex Type 2, sponsored by Genocea Biosciences, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-10-16.

Sponsored by Genocea Biosciences, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Herpes Simplex with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Herpes Simplex · United States.

Enrollment
10th of 66
310 · median 60
Started
2014
with 3 others
Phase 2
14 of 95
1 open now
Registered
66th of 95
by date
Lead sponsor
6 of 95
Genocea Biosciences, Inc.

Among the 95 studies in Herpes Simplex with a site in United States, this one is the 10th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2014, is one of 14 in phase 2, and was the 66th registered.

Herpes Simplex

166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.

Browse Herpes Simplex studies →

Open to participants now

5 of the 95 studies in Herpes Simplex with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Herpes Simplex with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, factorial study to compare the reduction in viral shedding among 6 different combinations of GEN-003, a therapeutic HSV-2 vaccine and Matrix-M2 adjuvant.

Secondary objectives of the study include:

  • Evaluation of the safety and tolerability of GEN-003 in combination with Matrix-M2 compared to placebo.
  • Comparison of the impact on clinical Herpes Simplex Virus type-2 (HSV-2) disease among the 6 different combinations of GEN-003 antigens and Matrix-M2 adjuvant measured by:

    • Time to first clinical and/or virologic recurrence,
    • Proportion of subjects who are recurrence free at 6 and 12 months after the last dose of vaccine,
    • Lesion rate (percent of days with genital lesions present) during the post-vaccination swabbing periods.
  • Evaluation of cellular and humoral responses to GEN-003 antigens.

Additional objectives include:

  • Assessment of the correlation between immune responses and change in viral shedding or impact on clinical disease as defined above.
  • Determination of the recurrence rate in a subset of subjects not receiving suppressive antivirals throughout the study.

Eligible subjects will enter a baseline period to collect anogenital swabs for 28 consecutive days prior to randomization. Each subject will receive up to 3 doses at 21 day intervals. Subjects will be followed for safety and immunologic response for 12 months following their last dose.

03

Conditions studied

  • Genital Herpes Simplex Type 2

Browse trials for

Keywords

  • HSV
  • Herpes
  • genital infection
  • vaccine
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and non-pregnant females, ages 18 to 50 years inclusive.
  • Diagnosis of genital HSV-2 infection for > 1 year supported by ONE of the following documented in the medical history or performed at screening:

    • Western blot for HSV-2
    • Type-specific polymerase chain reaction (PCR) or viral culture
    • Compatible clinical history AND
  • Positive HerpeSelect® 2 Enzyme-linked Immunosorbent Assay (ELISA) Immunoglobulin G (IgG) with an index value >3.5, or
  • Positive LIAISON® HSV-2 Type-Specific IgG
  • A history of at least 3 and no more than 9 reported clinical occurrences in the prior 12 months, or, if currently on suppressive therapy, history of at least 3 and no more than 9 reported clinical occurrences in the 12 months prior to initiation of suppressive therapy.
  • Collection of at least 45 of 56 anogenital swabs during the baseline period.
  • Willing and able to provide written .
  • Willing to perform and comply with all study procedures including attending clinic visits as scheduled.
  • Men and women of , must be willing to practice a highly effective method of that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device (IUD), or barrier method (e.g., condom, diaphragm) for 28 days before and 90 days after receiving Study Drug.

Exclusion criteria

Exclusion Criteria:

  • On suppressive antiviral medication within 7 days of beginning baseline anogenital swab collection period.
  • History of genital Herpes Simplex Virus type-1 (HSV-1) infection.
  • History of any form of ocular Herpes Simplex Virus (HSV) infection, HSV-related erythema multiforme, or herpes meningitis or encephalitis.
  • individuals, including those receiving immunosuppressive doses of (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled corticosteroids [> 960 μg/day of beclomethasone dipropionate or equivalent]) or other immunosuppressive agents.
  • Presence or history of disease, regardless of current treatment.
  • Positive serologic test for (HIV-1) or infection; positive surface antigen (HBsAg).
  • laboratory abnormality or a value ≥ Grade 2.
  • Prior immunization with a vaccine containing HSV-2 antigens.
  • History of to any component of the vaccine.
  • Receipt of any drug within 30 days prior to the first dose of Study Drug.
  • Receipt of blood products within 90 days prior to the first dose of Study Drug.
  • Receipt of a within 28 days prior to or a subunit vaccine within 14 days prior to the first dose of Study Drug or planned vaccination within 30 days following the last dose of Study Drug.
  • Pregnant or nursing women.
  • History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study.
  • Other active, uncontrolled co-morbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.

NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to the first dose of Study Drug.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    GEN-003 Vaccine 30μg / Matrix-M 25μg

    GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (30μg of each antigen) · Biological: Matrix-M2 Adjuvant (25μg)

  • Experimental
    GEN-003 Vaccine 30μg / Matrix-M2 50μg

    GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (30μg of each antigen) · Biological: Matrix-M2 Adjuvant (50μg)

  • Experimental
    GEN-003 Vaccine 30μg / Matrix-M2 75μg

    GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (30μg of each antigen) · Biological: Matrix-M2 Adjuvant (75μg)

  • Experimental
    GEN-003 Vaccine 60μg / Matrix-M2 25μg

    GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (60μg of each antigen) · Biological: Matrix-M2 Adjuvant (25μg)

  • Experimental
    GEN-003 Vaccine 60μg / Matrix-M2 50μg

    GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (60μg of each antigen) · Biological: Matrix-M2 Adjuvant (50μg)

  • Experimental
    GEN-003 Vaccine 60μg / Matrix-M2 75μg

    GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.

    Biological: GEN-003 Vaccine (60μg of each antigen) · Biological: Matrix-M2 Adjuvant (75μg)

  • Placebo comparator
    Placebo

    0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.

    Biological: Placebo

Interventions

  • HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

    Also known as: HSV Vaccine

  • HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D

    Also known as: HSV Vaccine

  • Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

    Also known as: MM2, Adjuvant

  • Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

    Also known as: MM2, Adjuvant

  • Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

    Also known as: MM2, Adjuvant

  • BiologicalPlacebo

    0.9% Normal Saline (NaCl)

    Also known as: 0.9% Normal Saline (NaCl)

06

What researchers measure

Primary outcomes

  1. Change in proportion of days with detectable viral shedding

    Time frame: 6 weeks

Secondary outcomes

  1. Immunogenicity measured by humoral (antibody) and T-cell responses to vaccine antigens

    Time frame: 33 weeks

  2. Impact on clinical HSV-2 disease based on time to recurrence and lesion rate

    Time frame: 53 weeks

  3. Number of patients with adverse events as a measure of safety and tolerability

    Time frame: 57 weeks

07

Study locations

16 sites
  • University of Alabama Vaccine Research Unit
    Birmingham, Alabama 35294-0006, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • University of Illinois Department of Medicine
    Chicago, Illinois 60612, United States
  • Indiana University Infectious Disease Research
    Indianapolis, Indiana 46202, United States
  • The Fenway Institute
    Boston, Massachusetts 02215, United States
  • UNC Global HIV Prevention and Treatment Clinical Trials Unit
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Westover Heights Clinic
    Portland, Oregon 97210, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Tekton Research
    Austin, Texas 98745, United States
  • Center for Clinical Studies - Houston
    Houston, Texas 77030, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Center for Clinical Studies - Clear Lake/Webster
    Webster, Texas 77598, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • UW Virology Research Clinic
    Seattle, Washington 98104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2014
First posted
Apr 15, 2014
Start
Jul 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results delay requested
Sep 11, 2017
Last update
Oct 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02114060
Lead sponsor
Genocea Biosciences, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Jul 2014
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Oct 16, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GEN-003 · Adjuvant

Start the discussion